Get the Stockscreener App
106.38
0.97%
-1.04
After Hours:
110.25
3.87
+3.64%
Guardant Health Inc stock is traded at $106.38, with a volume of 1.62M.
It is down -0.97% in the last 24 hours and down -5.14% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$107.42
Open:
$106.61
24h Volume:
1.62M
Relative Volume:
0.80
Market Cap:
$13.82B
Revenue:
$902.57M
Net Income/Loss:
$-398.79M
P/E Ratio:
-33.11
EPS:
-3.2131
Net Cash Flow:
$-274.52M
1W Performance:
+3.52%
1M Performance:
-5.14%
6M Performance:
+81.63%
1Y Performance:
+117.10%
1-Day Range:
$104.90
$108.85
1-Week Range:
$102.00
$110.46
52-Week Range:
$34.88
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
106.38 | 13.95B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health (GH) Achieves Strong Revenue Growth in Q4 2025 - GuruFocus
Guardant Health Reports Strong Q4 2025 Earnings with Significant Growth - Intellectia AI
Guardant Health Q4 Earnings Call Highlights - Yahoo Finance
Guardant Health: Q4 Earnings Snapshot - theheraldreview.com
Compared to Estimates, Guardant Health (GH) Q4 Earnings: A Look at Key Metrics - Yahoo Finance UK
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Guardant Health: Fourth Quarter Financial Overview - Bitget
Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales - Finviz
Guardant Health (GH) Shares 2026 Financial Outlook with Improved Margins - GuruFocus
GH Reports Strong Q4 Revenue, Highlights Future Growth Prospects - GuruFocus
Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results - MarketBeat
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook - Yahoo Finance
Guardant Health earnings up next: Can Shield growth offset losses? By Investing.com - Investing.com Canada
GSA Capital Partners LLP Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (NASDAQ:GH) Rating Increased to Strong-Buy at Robert W. Baird - MarketBeat
Guardant Health, Inc. $GH Shares Bought by Eagle Health Investments LP - MarketBeat
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow - Finviz
Guardant Health Q4 2025 Earnings Report Date & Analyst ForecastsNews and Statistics - IndexBox
What Makes Guardant Health (GH) a Good Healthcare Holding - Finviz
Guardant Health (GH): Baird Initiates Coverage with Outperform R - GuruFocus
Baird initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com South Africa
Baird initiates Guardant Health stock coverage with outperform rating - Investing.com
North America Liquid Biopsy Market to Reach US$ 5110.34 Million - openPR.com
Guardant Health, Inc. (GH) Stock Analysis: Riding the 19.45% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Published on: 2026-02-14 21:22:46 - mfd.ru
A Look At Guardant Health (GH) Valuation As New ctDNA Study Supports Guardant Reveal In Colon Cancer - Yahoo Finance
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why (GH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Cancer Profiling Market Size, Share | Growth Report [2034] - Fortune Business Insights
Top Cancer Stocks for 2026 and How to Invest - The Motley Fool
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open - Yahoo Finance
GoFundMe for James Van Der Beek’s family surpasses $1.5M in less than 24 hours - Austin American-Statesman
Guardant Health Shares Slide as Principal Cuts Stake and Insiders Sell - CryptoRank
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Guardant Health, Inc. $GH Shares Sold by Principal Financial Group Inc. - MarketBeat
Travel Stocks: How does Guardant Health Inc compare to its peersJuly 2025 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Guardant Health Inc (GH) Trading Down 4.5% on Feb 11 - GuruFocus
Minimal Residual Disease Testing Market Poised for Rapid Growth - openPR.com
Aug Momentum: Is now the right time to enter Guardant Health IncJuly 2025 Fed Impact & Verified Stock Trade Ideas - baoquankhu1.vn
New York State Common Retirement Fund Has $4.77 Million Stake in Guardant Health, Inc. $GH - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Lowers Position in Guardant Health, Inc. $GH - MarketBeat
A Congress Member Sold Up To $125K In McDonald's Stock: Here's What You Need To Know - Benzinga
ETF Watch: Is now the right time to enter Guardant Health Inc2025 Volume Leaders & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Guardant Health to Participate in Upcoming Investor ConferencesFebruary 3, 2026 - BioSpace
Precision oncology firm Guardant lines up four investor talks - stocktitan.net
Guardant Health ctDNA test sets new standard in cancer detection - Traders Union
Guardant Health guides Q4 and FY25 revenue above consensus - MSN
Understanding Momentum Shifts in (GH) - Stock Traders Daily
Merck Eyes Post Keytruda Growth With Eikon Stake And Guardant Pact - Yahoo Finance
Guardant Health (GH) Study Highlights Advancements in Colon Canc - GuruFocus
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):